Trial reportHeart (British Cardiac Society)2007
Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy.
Trial report in Heart (British Cardiac Society), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis.Drugs in R&D · 2023Pooled it
- Metabolic Modulation in Dilated Cardiomyopathy: From Pathophysiology to Therapy.Reviews in cardiovascular medicine · 2025Review
- Prognostic impact of angiography-derived index of microcirculatory resistance in patients with dilated cardiomyopathy.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition).MedComm · 2023Review
- Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know.Current atherosclerosis reports · 2023Review
- Effect of Beta Blockers on the Hemodynamics and Thrombotic Risk of Coronary Artery Aneurysms in Kawasaki Disease.Journal of cardiovascular translational research · 2023Article
- Updates on Pharmacologic Management of Microvascular Angina.Cardiovascular therapeutics · 2022Review
- Myocardial Microvascular Physiology in Acute and Chronic Coronary Syndromes, Aortic Stenosis, and Heart Failure.Journal of interventional cardiology · 2022Article
- Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM).European journal of nuclear medicine and molecular imaging · 2016Review
- Burn-associated delayed dilated cardiomyopathy evaluated by cardiac PET and SPECT: Report of a case.Journal of cardiology cases · 2014Article
- Abnormal glucose and lipid control in non-ischemic left ventricular dysfunction.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2012Article
- Non-invasive quantification of coronary vascular dysfunction for diagnosis and management of coronary artery disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2012Review
- Quantitative cardiac positron emission tomography: the time is coming!Scientifica · 2012Review
- Use of carvedilol in hypertension: an update.Vascular health and risk management · 2012Review
- Beta-blockers and coronary flow reserve: the importance of a vasodilatory action.Drugs · 2008 · on this mapReview
- Detecting the impact of emerging cardiovascular risk factors: the role of positron emission tomography.Journal of nuclear cardiology : official publication of the American Society of Nuclear CardiologyArticle
- Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy.Journal of nuclear cardiology : official publication of the American Society of Nuclear CardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess whether chronic treatment with carvedilol can increase myocardial blood flow (MBF) and MBF reserve in idiopathic dilated cardiomyopathy (IDC). STUDY
designIn a double-blind, placebo-controlled trial, 16 consecutive patients with IDC were randomised to treatment with either carvedilol up to 25 mg twice a day (n = 8, 7 men, mean (SD) age 60 (9) years, mean (SD) left ventricular ejection fraction (LVEF) 30% (5%)), or placebo (n = 8, 6 men, mean (SD) age 62 (9) years, mean (SD) LVEF 28% (6%), NS vs carvedilol group). Before and 6 months after treatment, regional MBF was measured at rest and after intravenous injection of dipyridamole (Dip; 0.56 mg/kg in 4 min) by positron emission tomography and using (13)N-ammonia as a flow tracer. Exercise capacity was assessed as the time duration in a maximal bicycle exercise stress test.
resultsCarvedilol induced a significant decrease in heart rate at rest and during maximal exercise, and an increase in exercise capacity. Absolute MBF values did not significantly change after carvedilol or placebo treatment, either at rest or during Dip injection, although Dip-MBF tended to improve after treatment. Coronary flow reserve significantly increased following carvedilol treatment (from 1.67 (0.63) to 2.58 (1.04), p<0.001), whereas it remained unchanged following the placebo treatment (from 1.80 (0.84) to 1.77 (0.60), NS). Stress-induced regional perfusion defects decreased after carvedilol treatment (from 38% to 15%).
conclusionsLong-term treatment with carvedilol can significantly increase coronary flow reserve and reduce the occurrence of stress-induced perfusion defects, suggesting a favourable effect of the drug on coronary microvascular function in patients with IDC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.